Replies to post #410593 on Amarin Corp Plc (AMRN)

[JRoon71]

I'm not sure $5/share makes any sense.

The way I look at it, the company is either worthless, or it's worth at least $8-10. Because $5/share is only $2B, which implies roughly $450-500M in peak revenues (and not even considering cash & inventory). This would suggest that there is ZERO upside in revenue from here forward. And if there is no growth in revenues from here, then nobody would buy them anyway. Maybe they would get bought for the IP, but that's about it. And I think the IP is probably worth more than that.

Really, I think Vascepa is a headscratcher. Definitely an effective and super-safe drug. But it's more like a preventative "superfood" than a drug. A supplement on crack. One that most insurance companies and countries don't want to pay for. So I think it is very confusing for a BP to wrap their heads around. I think it HAS to be sold alongside another CV drug (ie. statins, etc.) for it to work for a BP.